Trial · NCT03808688
Adverse events14
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 14 of 14
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Conjunctival Hyperemia | Eye disorders | Netarsudil Ophthalmic Solution 0.02% Monotherapy | 22 | 99 | 22 |
| other | Conjunctival Hyperemia | Eye disorders | Netarsudil Ophthalmic Solution 0.02% Concomitant Therapy | 32 | 161 | 32 |
| other | Vision Blurred | Eye disorders | Netarsudil Ophthalmic Solution 0.02% Monotherapy | 9 | 99 | 9 |
| other | Vision Blurred | Eye disorders | Netarsudil Ophthalmic Solution 0.02% Concomitant Therapy | 10 | 161 | 10 |
| other | Conjunctival Hemorrage | Eye disorders | Netarsudil Ophthalmic Solution 0.02% Monotherapy | 6 | 99 | 6 |
| other | Conjunctival Hemorrage | Eye disorders | Netarsudil Ophthalmic Solution 0.02% Concomitant Therapy | 8 | 161 | 8 |
| other | Instillation Site Pain | Eye disorders | Netarsudil Ophthalmic Solution 0.02% Monotherapy | 6 | 99 | 6 |
| other | Instillation Site Pain | Eye disorders | Netarsudil Ophthalmic Solution 0.02% Concomitant Therapy | 8 | 161 | 8 |
| serious | Cellulitis Lower Left Extremity | Infections and infestations | Netarsudil Ophthalmic Solution 0.02% Monotherapy | 0 | 99 | 0 |
| serious | Cellulitis Lower Left Extremity | Infections and infestations | Netarsudil Ophthalmic Solution 0.02% Concomitant Therapy | 1 | 161 | 1 |
| serious | Malignant Melanoma of Eyelid | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Netarsudil Ophthalmic Solution 0.02% Monotherapy | 1 | 99 | 1 |
| serious | Malignant Melanoma of Eyelid | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Netarsudil Ophthalmic Solution 0.02% Concomitant Therapy | 0 | 161 | 0 |
| serious | Pneumonia | Infections and infestations | Netarsudil Ophthalmic Solution 0.02% Monotherapy | 1 | 99 | 1 |
| serious | Pneumonia | Infections and infestations | Netarsudil Ophthalmic Solution 0.02% Concomitant Therapy | 0 | 161 | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03808688/events